ServiceNow (NOW) — Graham-Style Analysis #

Date: 2026-03-23 | Source: yfinance, SEC Form 4s, StockAnalysis, web search

1. Price & Market Cap #

2. Valuation Ratios #

Key observation on P/E gap: Trailing P/E 66x vs Forward P/E 22x — a 3:1 ratio. Per shr-003, this reveals the market pricing a profitability inflection (GAAP earnings expected to roughly triple from $1.67 → ~$5.02), not sustained high historical growth. The relevant multiple for current entry is forward, not trailing.

3. Revenue & EPS Growth #

Revenue (Annual) #

3-year revenue CAGR (2022-2025): ~22.4%. Highly consistent — NOW has decelerated only slightly.

GAAP Diluted EPS (Annual) #

Earnings stability: GAAP EPS has been positive every year in the data available (2021-2025 = 5 consecutive positive years). Pre-2021 data: NOW generated net losses in 2017-2019, turned GAAP profitable in 2020. This means NOW does NOT have 10+ years of unbroken profitability — it fails Graham's earnings stability filter on strict interpretation.

Quarterly EPS Beat History (Non-GAAP aligned): #

• Q4 FY2026 (Jan 2026): $0.92 actual vs $0.89 est (+3.9%)
• Q3 FY2026 (Oct 2025): $0.96 actual vs $0.85 est (+13.0%)
• Q2 FY2026 (Jul 2025): $0.82 actual vs $0.71 est (+14.6%)
• Q1 FY2026 (Apr 2025): $0.81 actual vs $0.77 est (+5.4%) Consistent beats for 4+ quarters. Next earnings: 2026-04-22.

4. Free Cash Flow & SBC-Adjusted FCF #

This is the most important section for valuation. Per shr-001, SBC is a real cost.

P/FCF Multiples (at $110.38 / $116.5B market cap) #

Critical finding: Reported FCF looks reasonable at 25.7x. SBC-adjusted FCF nearly doubles the multiple to 45.2x. SBC consumed 43% of reported FCF in 2025. The trend is improving (from 65% in 2022 → 43% in 2025) as the business scales, but SBC remains substantial. At 45.2x SBC-adjusted P/FCF, the stock is priced for continued high-growth execution — not a Graham defensive buy.

5. Balance Sheet #

D/E ratio note: yfinance reports 18.5 — this appears to include deferred revenue liabilities which are not financial debt. The company is net cash positive ($1.32B), so actual financial leverage is low. Interest coverage: 99x (EBIT $2.28B / Interest $23M). Balance sheet is very strong.

Graham current ratio concern: 1.003x is significantly below Graham's 2x minimum. However, NOW's large deferred revenue (SaaS subscriptions paid upfront) inflates current liabilities — the cash underlying those subscriptions has already been collected. This is a reporting artifact of subscription business models, not financial distress (parallel to shr-015 for financial sector).

Share dilution: From 1,014M shares (2022) to 1,047M shares (2025) = +3.2% over 3 years (~1.1%/yr net). Modest — buybacks are partially offsetting SBC grants.

6. Dividend #

None. ServiceNow pays no dividend. Fails Graham's defensive filter requiring uninterrupted dividends for 20+ years.

7. Insider Activity (Last 6 Months) #

McDermott CEO Purchase — HIGH CONVICTION SIGNAL #

Coordinated Signal — Beyond the $3M Purchase #

Per web search (Form 8-K and Form 4 filings, Feb 2026):

• McDermott pre-announced the $3M purchase in a Form 8-K on Feb 13, 2026 — maximum transparency
• Five executives simultaneously terminated their Rule 10b5-1 automatic selling plans: McDermott (CEO), Gina Mastantuono (President/CFO), Nicholas Tzitzon (Vice Chairman), Jacqueline Canney (CPO), Russell Elmer (Special Counsel)
• Cancelling future automatic sales = management is betting on the stock going higher

6-Month Aggregate (per yfinance insider_purchases summary) #

Per shr-002: The CEO is spending $3M of his own money in an open-market purchase at ~$105. Five executives cancelled automated sales plans. This is a far stronger signal than RSU exercises or option grants. The buy/sell ratio (~23:1 by share count) is significantly bullish. However, "significant" must be weighed against the full picture.

8. Analyst Consensus #

vs Current Price $110.38:

• Mean target implies +70.9% upside
• Median target implies +65.3% upside
• Low target implies +11.2% upside — the floor of analyst expectations is still above current price

Consensus is overwhelming: 41 Buy/Strong Buy vs 4 Hold/Sell. Rating unchanged month-over-month.

9. Short Interest #

No short squeeze mechanics — 2.5% short interest is negligible. This is not a squeeze story.

10. Graham Intrinsic Value: V = EPS × (8.5 + 2g) #

Using Trailing GAAP EPS ($1.67) #

At trailing EPS, NOW is overvalued at ANY reasonable growth rate. But trailing EPS is suppressed by ~$1.87 of SBC/tax/timing effects — GAAP EPS understates business economics.

Using Forward GAAP EPS ($5.02, FY2026 consensus) #

Break-even growth rate: ~6.6% long-term — if you believe NOW can grow GAAP EPS at more than 6.6%/yr long-term, the forward-basis Graham formula says the stock is fair or cheap. Given 20%+ revenue growth and improving GAAP margins, 6.6% EPS growth looks very achievable — implying the stock has upside at 10%+ growth scenarios.

The key inflection: The GAAP EPS is projected to jump from $1.67 (FY2025) to $5.02 (FY2026) — a ~3x increase in one year. This is the profitability inflection that makes trailing-basis analysis nearly useless (per shr-003 and shr-004).

11. Graham 7-Filter Defensive Screen #

Score: 1 hard PASS, 1 partial, 5 FAIL.

NOW fails the Graham defensive screen comprehensively, as expected for a high-growth tech compounder. This does not mean it's a bad investment — it means it must be evaluated as a growth stock, not a defensive stock.

12. Growth Stock Addendum (per shr-004) #

Per the Growth Stock Addendum framework: buy when implied growth from current P/E is ≤ achievable growth rate, with margin.

• Forward P/E: 22x → Graham growth formula implies: (22 - 8.5) / 2 = 6.75% implied growth rate
• Achievable growth estimate: Revenue growing 20-22% per year; GAAP EPS growing faster due to operating leverage; non-GAAP (cash) EPS growing ~15-20%. Conservative long-term sustainable estimate: 12-18%.
• Verdict: If NOW can sustain 12%+ long-term EPS growth (highly plausible), the forward P/E of 22x implies the growth is NOT priced in — the stock would be undervalued. At 10% growth, the Graham formula gives IV of $143 vs $110 price = +29.6% margin of safety.

Summary Verdict: Reddit Thesis Assessment #

The claim: "NOW is cheap at 50% off highs."

Verdict: Nuanced — cheap vs highs, but not cheap on trailing Graham metrics.

What the bull case gets right: #

1. The stock is -47.8% from its 52-week high — significant compression
2. CEO purchased $3M of stock open-market at $104-106, and five executives cancelled auto-sell plans — very strong insider signal (shr-002)
3. Forward P/E of 22x is reasonable for a 20%+ revenue compounder with dominant market position
4. At 10%+ long-term growth, the Graham formula (forward EPS) implies 30%+ upside
5. Analyst consensus: 41/45 analysts rate Buy/Strong Buy, median PT $182.50 (+65%)
6. Revenue growth: 20-23% for 4 consecutive years — no slowdown visible
7. Balance sheet: net cash positive $1.32B, 99x interest coverage

What the bull case hides (hard numbers): #

1. Trailing P/E: 66x — this is the "cheap" stock. On GAAP trailing, it has never been a Graham buy.
2. SBC is massive: $1.96B in 2025 = 43% of reported FCF. True owner's FCF is $2.58B, not $4.53B. P/SBC-adjusted FCF = 45.2x — expensive.
3. Graham formula fails on trailing EPS at every growth rate up to 25%.
4. No dividend. No 20-year earnings history. Classic growth tech — 0/7 on Graham's strict defensive filters (or at best 1/7).
5. Current ratio 1.003x — technically fails Graham's filter (though it's a SaaS accounting artifact).
6. SBC dilution: $1.96B/year in compensation is funded by shareholders even if share count looks stable.
7. Earnings stability: GAAP losses pre-2020. Profitable only for ~5-6 years. Does not meet Graham's long earnings history standard.

The honest framing: #

NOW at $110 is a growth stock at a compressed valuation — it is not a Graham defensive bargain. The "cheap" argument only works if you accept:

• Forward GAAP EPS of $5.02 (a 3x jump from FY2025's $1.67)
• Long-term EPS growth of 10-15%
• That SBC-adjusted FCF is the right lens, not Graham GAAP EPS

If those conditions hold, the stock has 30-70% upside. If the FY2026 earnings inflection disappoints, the forward P/E blows back out and there is no valuation floor.

Bottom line for an Intelligent Investor framework: NOT a Graham defensive buy. Could be a Growth Stock Addendum candidate if you have conviction on the GAAP profitability inflection and trust the insider signal. The $3M CEO purchase at $104-106 is the single most compelling data point. At 22x forward P/E with 20% revenue growth and a CEO buying $3M of stock, it is arguably the most compelling growth stock setup in large-cap software right now — but you need a growth framework, not a Graham defensive framework, to justify it.

Sources: yfinance (price, financials, insider data), SEC Form 4 / Form 8-K (McDermott purchase), StockAnalysis.com (historical financials), web search (insider context)